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outcomes are observed between such gene-
ric and reference medicines, recent evidence 
suggests that this does not result from issues 
surrounding bio-equivalence, but from other 
factors such as undue concerns from patients 
or physicians about the effectiveness of ge-
neric medicines or the act itself of refilling a 
prescription [2,4].
Due to their lower costs of research and de-
velopment (as there is for example no need to 
replicate pre-clinical tests and clinical trials), 
generic medicines tend to be less expensive 
than reference medicines. Vogler et al. [5] 
calculated the difference in ex-factory prices 
between five generic and reference medici-
nes for 16 European countries in November 
2011. These authors found that price diffe-
rences between generic and reference medi-
cines were limited or non-existent for some 
countries, but varied between 50% and ap-
proximately 100% for other countries. Larger 
price differences between generic and refe-
rence medicines and lower generic medicine 
prices tended to be observed in countries that 
had implemented effective generic medicine 
policies based on competition and enforce-
ment (such as mandatory generic substitution 
and/or prescribing by international non-pro-
prietary name).
As a result of their lower price, generic medi-
cines play a crucial role in sustaining patient 
access to health care. Generic medicines are 
today used in the treatment of acute as well 
as chronic diseases such as asthma, bacterial 
infections, cancer, diabetes, depression, epi-
lepsy, gastro-intestinal and inflammatory di-
sorders, osteoporosis, pain, Parkinson’s dise-
ase and rheumatoid arthritis. The availability 
of generic medicines not only improves the 
cost-effectiveness of existing pharmacothe-
rapy, but may also make it cost-effective to 
manage previously untreated patients.
Therefore, Godman et al. [6] explored the 
contribution that low-priced generic me-
dicines can make to enhance prescribing 
efficiency and support comprehensive and 
equitable health care. This review of the Eu-
ropean experience showed that the imple-
mentation of various supply-side measures 
(i.e. measures related to market access, (refe-
INTRODUCTION
Once intellectual property protection, data 
and marketing exclusivity of reference me-
dicines have expired, generic medicines and 
biosimilar medicines can enter the off-patent 
market. This market entry is conditional on 
the approval of marketing authorization, 
pricing and reimbursement. Given that the-
re tends to be confusion surrounding gene-
ric and biosimilar medicines, this Editorial 
introduces basic concepts related to generic 
and biosimilar medicines and presents the 
different studies and articles included in this 
supplement dedicated to generic and biosimi-
lar medicines.
GENERIC MEDICINES
A generic medicine is a medicinal product 
which has the same qualitative and quantita-
tive composition in active substances as the 
reference chemical medicine; has the same 
strength, pharmaceutical form and admini-
stration route as the reference chemical me-
dicine; and has the same bio-availability as 
the reference chemical medicine as demon-
strated by appropriate bio-availability studies 
[1].
There has been controversy over whether 
differences in bio-availability that fall within 
the variation allowed by medicines agencies 
can lead to a different safety and efficacy 
profile between the generic medicine and the 
reference medicine. This controversy does 
not relate to the majority of small molecule 
medicines, where the generic medicine has 
the same quality, safety and efficacy as the re-
ference medicine and, therefore, the generic 
and reference medicines are interchangeable.
The question of bio-equivalence tends to be 
asked with respect to narrow therapeutic in-
dex medicines (e.g. anti-epileptic medicines), 
where the difference between the effective 
dose and the toxic dose is small. Concerns 
about bio-equivalence in narrow therapeutic 
index medicines seems to be unwarranted 
as multiple literature reviews have suppor-
ted the clinical equivalence of generic and 
reference versions of narrow therapeutic in-
dex medicines [2,3]. If differences in health 
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rence) pricing and reimbursement of generic 
medicines) and demand-side measures (i.e. 
incentives for physicians, pharmacists and 
patients to use generic medicines) has redu-
ced generic medicine prices and supported 
their utilization. This has allowed countries 
to save resources without compromising the 
quality, safety and efficacy of care.
However, market access of generic medici-
nes in Europe is inhibited or delayed by the 
decline in true innovation in the pharmaceu-
tical sector; shortcomings in current procedu-
res governing intellectual property protection 
(e.g. patent linkage, evergreening tactics), 
data and marketing exclusivity, and marke-
ting authorization; pricing and reimburse-
ment delays for generic medicines. There 
is a need to prevent evergreening tactics; to 
delink intellectual property protection issues 
from marketing authorization, pricing and 
reimbursement procedures; and to speed up 
pricing and reimbursement decisions for ge-
neric medicines [7].
BIOSIMILAR MEDICINES
In the case of biological medicines, a biosi-
milar medicine can enter the off-patent mar-
ket which is similar, but not identical to the 
reference medicine. In the European Union, 
marketing authorization of biosimilar medi-
cines is granted by considering non-clinical 
studies, comparative quality and pharmaco-
kinetic studies, pharmacodynamic studies, 
toxicology studies, comparative clinical effi-
cacy and tolerability studies [8].
The expiry of intellectual property protec-
tion, data and marketing exclusivity on biolo-
gical medicines will not only open the door to 
the development of biosimilar medicines, but 
will also enable the traditional generic medi-
cines industry to move from a ‘copy-cat’ bu-
siness model to an innovative business model 
that relies on investment in research and de-
velopment, and on the creation of expertise 
in biological development and manufactu-
ring. Based on qualitative research, Barei et 
al. [9] showed that the switch from generic to 
biosimilar medicines appears to be driven by 
the lack of innovation in product portfolios, 
price pressure, competition and industrial 
evolution. At the same time, the development 
of biosimilar medicines is a source of innova-
tion in itself as it requires the application of 
new technical, scientific, economic and com-
mercial competencies. In this way, biosimilar 
medicines can provide a significant societal 
contribution by means of cost reduction and 
improved access to high-quality, innovative 
pharmacotherapy.
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